We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Discovery of Protein's "QR Code" Could Aid Drug Development

A translucent pill surrounded by chemical structures
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, have identified how a protein receptor targeted by about 33% of all federally approved medication works. The discovery could facilitate pharmaceutical research because how and why this protein chooses to link to other proteins is critical to how cells will respond to medicines.


The recently published Nature Communications study, “Dynamic spatiotemporal determinants modulate GPCR:G protein coupling selectivity and promiscuity,” uncovered a cell signaling mechanism of the largest superfamily of drug target proteins, called G-protein coupled receptors (GPCRs). Located in the cell membrane, GPCRs bind to substances outside the cell, which in turn initiates coupling of GPCRs to G proteins, leading to biological changes in the cell. Mutations in GPCRs and G proteins have been implicated in cancer and diabetes. 


“Using large-scale data analysis techniques, we have identified the rules of engagement of GPCRs with G proteins — or the ‘QR code’ for their coupling,” said Nagarajan Vaidehi, Ph.D., the senior author of the study and chair of the Department of Computational and Quantitative Medicine at City of Hope. “Understanding the coupling mechanism of GPCRs to G proteins will aid in the design of drugs with lower side effects that target cancer-associated mutations.” 


Researchers can use the QR code to design small molecule drugs that specifically affect the coupling of a target GPCR to a specific G protein. Such a drug will affect only the cell signaling pathways that are cancer-associated and leave the other pathways unaffected. This process would lead to cleaner and more targeted cancer therapies. 


“We are using the QR code to identify more target-specific drugs,” Vaidehi said. “These findings are generalizable to any protein-to-protein coupling, which are emerging targets in personalized medicine,” Vaidehi said. 


Reference: Sandhu M, Cho A, Ma N, et al. Dynamic spatiotemporal determinants modulate GPCR:G protein coupling selectivity and promiscuity. Nat Commun. 2022;13(1):7428. doi: 10.1038/s41467-022-34055-5



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.